{"title":"Study of the safety of application of the drug \"Protostop\" in cryptosporidiosis of calves","authors":"N. Gavrilova, L. Belova, Y. A. Shcherbina","doi":"10.52419/issn2072-2419.2021.4.46","DOIUrl":null,"url":null,"abstract":"The drug \"Protostop\" containing 100.0 mg of paromomycin sulfate in 1.0 g was used in calves with cryptosporidiosis.The animals in the experimental groups were given the drug at a dose of 250 and 350 mg per 1 kg of animal weight individually, orally, in courses of 3 and 5 days, respectively. Before use, a single dose of the drug was dissolved in water by adding liquid to the powder. The calves of the control group received symptomatic treatment aimed at eliminating the diarrheal syndrome. Before the start of the therapeutic course and on the 10th day after its completion, blood was taken from the animals of the experimental and control groups for general clinical analysis.The physiological state of the animals was recorded before the administration of the drug and on the 4th, 6th, 8th, 12th and 15th day from the start of treatment. It was found that the treatment of calves with cryptosporidiosis with the drug \"Protostop\" at a dose of 250 mg/kg and 350 mg/kg in 3 and 5 -day courses did not cause negative changes in the animals' bodies. Before the start of the treatment, the hemoglobin content of the calves in all groups were lower than the reference values. Thrombocytopenia, eosinophilia and neutrophilia were also recorded and an increase in ESR was noted. After using the drug, the indices of eosinophils, segmented neutrophils and ESR were within the reference values, the hemoglobin level slightly increased. After using the drug, the indicators for eosinophils, segmented neutrophils and ESR were within the reference values, while the hemoglobin levels were slightly increased. Calves in the control group, despite symptomatic treatment, eosinophilia were observed with an increase in the percentage of segmented neutrophils and ESR. During the course of treatment, as well as 10 days after its completion, the calves showed no deterioration in their physiological state, hyperemia of the mucous membranes, itching or other signs indicating a possible side effect to the drug.","PeriodicalId":378052,"journal":{"name":"International bulletin of Veterinary Medicine","volume":"115 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International bulletin of Veterinary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52419/issn2072-2419.2021.4.46","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The drug "Protostop" containing 100.0 mg of paromomycin sulfate in 1.0 g was used in calves with cryptosporidiosis.The animals in the experimental groups were given the drug at a dose of 250 and 350 mg per 1 kg of animal weight individually, orally, in courses of 3 and 5 days, respectively. Before use, a single dose of the drug was dissolved in water by adding liquid to the powder. The calves of the control group received symptomatic treatment aimed at eliminating the diarrheal syndrome. Before the start of the therapeutic course and on the 10th day after its completion, blood was taken from the animals of the experimental and control groups for general clinical analysis.The physiological state of the animals was recorded before the administration of the drug and on the 4th, 6th, 8th, 12th and 15th day from the start of treatment. It was found that the treatment of calves with cryptosporidiosis with the drug "Protostop" at a dose of 250 mg/kg and 350 mg/kg in 3 and 5 -day courses did not cause negative changes in the animals' bodies. Before the start of the treatment, the hemoglobin content of the calves in all groups were lower than the reference values. Thrombocytopenia, eosinophilia and neutrophilia were also recorded and an increase in ESR was noted. After using the drug, the indices of eosinophils, segmented neutrophils and ESR were within the reference values, the hemoglobin level slightly increased. After using the drug, the indicators for eosinophils, segmented neutrophils and ESR were within the reference values, while the hemoglobin levels were slightly increased. Calves in the control group, despite symptomatic treatment, eosinophilia were observed with an increase in the percentage of segmented neutrophils and ESR. During the course of treatment, as well as 10 days after its completion, the calves showed no deterioration in their physiological state, hyperemia of the mucous membranes, itching or other signs indicating a possible side effect to the drug.